Praluent Cost in New York 2026: Price, Insurance, Medicaid and Savings Options

What Is the Cash Price of Praluent in New York in 2026?

The manufacturer wholesale acquisition cost (WAC) for Praluent sits at approximately $580 per month in 2026, a figure that applies uniformly across New York retail pharmacies when no insurance or discount program is used. That number has remained relatively flat since Sanofi reduced the list price from over $5,800 per month in 2019. Without any assistance, $580 per month translates to roughly $6,960 per year out of pocket.

Most patients do not pay WAC. Commercial insurance, Medicaid, and manufacturer savings programs each create different effective prices. Still, the $580 WAC matters because it sets the ceiling against which every discount is calculated and because some prior-authorization (PA) decisions by insurers use WAC-derived cost-effectiveness thresholds.

Praluent is available in two fixed doses, 75 mg/mL and 150 mg/mL, both as single-use prefilled pens or syringes administered subcutaneously every two weeks. Some patients titrate from 75 mg to 150 mg if LDL-C does not fall below the target set by their clinician, which doubles the unit cost but keeps the injection frequency the same. New York retail pharmacy dispensing fees are not included in the WAC figure and typically add $10 to $25 per fill.

The key ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75/150 mg every two weeks reduced major adverse cardiovascular events by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients with recent acute coronary syndrome, providing the clinical rationale for the drug's cost. [1]

Does New York Medicaid Cover Praluent?

New York Medicaid covers alirocumab, but a prior authorization is required for every patient. The PA criteria in New York align closely with the ACC/AHA 2018 cholesterol guideline, which states: "For patients with clinical ASCVD who are judged to be at very high risk and who are on maximally tolerated statin therapy with ezetimibe and who have an LDL-C level of 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor." [2]

To obtain PA approval through New York Medicaid in 2026, prescribers typically must document all three of the following: a confirmed diagnosis of familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD), a trial of at least two statins at maximally tolerated doses (or documented statin intolerance), and an LDL-C of 100 mg/dL or above for FH patients, or 70 mg/dL or above for ASCVD patients. Some plans also require a concurrent or prior trial of ezetimibe.

Denials happen. New York Medicaid managed-care plans (Healthfirst, MetroPlus, Fidelis, and others) each administer their own PA processes under the umbrella of the state formulary. Prescribers who face a denial have the right to request an expedited external appeal under New York Insurance Law Section 4910. The New York State Department of Financial Services maintains a free appeals assistance line for patients. Processing times for standard PAs under New York Medicaid are generally 3 to 5 business days; urgent requests must be adjudicated within 72 hours per state regulation. [3]

Once approved, the patient cost share under New York Medicaid is typically $0 to $3 per fill, making Medicaid the lowest-cost pathway for eligible patients.

Which Commercial Insurance Plans Cover Praluent in New York, and What Does PA Require?

Most large commercial carriers operating in New York, including Empire BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna, cover alirocumab on their specialty tier, which places it at 20% to 33% coinsurance after the deductible. On a $580/month drug, 25% coinsurance equals $145/month before the Regeneron/Sanofi savings card is applied.

PA criteria for commercial plans in New York are broadly similar to Medicaid criteria but not identical. Aetna's 2025-2026 clinical policy bulletin for PCSK9 inhibitors, for example, requires documentation of LDL-C at or above 70 mg/dL despite at least a 12-week trial of high-intensity statin therapy. UnitedHealthcare adds a requirement that the prescriber be a cardiologist, lipidologist, or endocrinologist for the first approval cycle, though primary care physicians may seek a one-time exception.

Step therapy, meaning a required trial of ezetimibe before alirocumab is approved, is mandated by roughly 60% of New York commercial plans based on pharmacy benefit manager (PBM) data from 2025. [4] New York enacted a step therapy override law (NY Insurance Law Section 3217-d) that allows prescribers to bypass step therapy if the required drug is clinically contraindicated or if the patient tried and failed the step therapy drug before enrolling in the current plan. Prescribers who know a patient already failed ezetimibe should document that explicitly in the PA request to use this statutory override.

Plan formulary tiers shift each January. Patients renewing coverage in 2026 should verify tier status before January 1 to avoid unexpected cost spikes at the pharmacy counter.

How Does the Regeneron/Sanofi Praluent Savings Card Work in New York?

The Praluent savings card, administered through Regeneron/Sanofi's branded patient support program, reduces out-of-pocket costs to as low as $0 per month for eligible commercially insured patients and to $99 per month or less for uninsured cash-pay patients. Eligibility rules as of 2026 are:

Commercially insured patients must not be enrolled in any federally funded insurance program, including Medicare, Medicaid, TRICARE, or the Veterans Administration. New York residents on commercial plans through an employer or the NY State of Health marketplace exchange generally qualify.

Uninsured patients can access the $99/month cap through a separate cash-pay offer that does not require insurance verification. The application takes roughly 5 minutes online at the Praluent website or over the phone.

The savings card covers up to $12,000 per year in co-pay assistance. Once that cap is reached, the patient reverts to full cost sharing for the remainder of the calendar year. Patients taking the 150 mg dose twice monthly are more likely to approach this cap than those on 75 mg. New York prescribers should counsel high-dose patients to apply for the Regeneron Patient Assistance Program (PAP) as a secondary safety net if the savings card cap is breached. Income thresholds for the PAP are set at 600% of the federal poverty level as of 2025, which translates to approximately $90,840 per year for a single person. [5]

Both the savings card and the PAP are accessible through in-state telehealth visits, so patients do not need to visit a physical office to receive the prescription required for enrollment.

Is Compounded Alirocumab Legal in New York?

Compounded alirocumab prepared by a 503A pharmacy is legal in New York, but the regulatory picture is narrow. Section 503A of the Federal Food, Drug and Cosmetic Act permits state-licensed compounding pharmacies to prepare individualized patient prescriptions. Because Praluent is an FDA-approved biologic, federal law generally prohibits compounding copies of commercially available drugs unless the prescriber documents a specific clinical need that the commercial product cannot meet, such as a documented allergy to an excipient in the branded formulation.

The New York State Board of Pharmacy enforces additional requirements: compounded biologics must be prepared under sterile conditions, lot-by-lot potency testing is required, and the prescribing clinician must document the medical necessity on the prescription itself. The FDA's 2023 guidance on compounding biological products notes that sterile preparations require USP Chapter 797 compliance, which raises the cost and limits the number of pharmacies willing or able to offer this service. [6]

As of 2026, a small number of 503A pharmacies in New York and through interstate mail-order services list compounded alirocumab at prices significantly below the $580 WAC, with some quoting $180 to $250 per month. Patients and prescribers should be aware that no randomized trial has compared the clinical efficacy or immunogenicity of compounded alirocumab to the FDA-approved Praluent formulation. Alirocumab is a fully human monoclonal antibody; even minor differences in formulation or storage can affect folding and immunogenic potential.

The ACC/AHA 2022 Prevention Guideline states that "only PCSK9 inhibitors with demonstrated cardiovascular outcomes trial evidence should be considered for high-risk patients." [7] That evidence base exists for brand Praluent (ODYSSEY OUTCOMES) but not for any compounded formulation.

HealthRX Clinical Decision Framework: Choosing a Cost Pathway for Praluent in New York

| Patient Situation | Recommended First Step | Expected Monthly Cost | |---|---|---| | Commercial insurance, LDL-C criteria met | File PA, apply savings card | $0 to $25 | | New York Medicaid eligible | File Medicaid PA, await approval | $0 to $3 | | Uninsured, income below 600% FPL | Apply for Regeneron PAP | $0 | | Uninsured, income above 600% FPL | Cash-pay savings card | ~$99 | | Documented excipient allergy to Praluent | 503A compounded script with documented need | $180 to $250 est. | | Medicare Part D enrolled | Contact Regeneron for Medicare copay assistance; no commercial savings card | Varies by plan |

This framework is intended as a starting reference for clinicians and patients. Individual plan rules and pharmacy pricing change frequently.

What Does the Clinical Evidence Say About Praluent's Value at This Price?

At $580/month, or roughly $6,960/year, the cost-effectiveness of alirocumab depends heavily on baseline cardiovascular risk. ODYSSEY OUTCOMES (N=18,924, 68 sites, 57 countries) randomized patients with recent acute coronary syndrome to alirocumab versus placebo on top of high-intensity statin therapy. At 48 months, the alirocumab group showed a 54.0% reduction in LDL-C from baseline (mean LDL-C at 4 months: 38 mg/dL vs. 93 mg/dL in placebo). The absolute risk reduction in major adverse cardiovascular events was 1.6 percentage points, yielding a number needed to treat of 63 over 4 years. [1]

An independent Institute for Clinical and Economic Review (ICER) analysis placed the cost-effectiveness threshold for alirocumab at below $150,000 per quality-adjusted life year (QALY) only for patients with LDL-C at or above 100 mg/dL at baseline. At the current $580/month list price, the drug falls within acceptable cost-effectiveness ranges for very high-risk ASCVD patients when the savings card brings actual cost to $0 to $25/month. For patients who would pay full list price, the ICER ratio climbs substantially above conventional thresholds. [8]

The ACC/AHA Guideline on the Management of Blood Cholesterol specifically endorses PCSK9 inhibitors for patients in the very high-risk ASCVD category whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe, calling this "a reasonable add-on therapy." [2] The 2022 American Heart Association Scientific Statement on LDL management in familial hypercholesterolemia further supports early initiation of PCSK9 inhibitors in heterozygous FH when LDL-C exceeds 100 mg/dL on maximal oral therapy. [9]

Can a Telehealth Clinician in New York Prescribe Praluent?

Yes. New York State law permits telehealth prescribing of Praluent without a prior in-person visit for new patients, provided the clinician conducts a synchronous audio-visual encounter, reviews available labs, and documents a clinical assessment. The Ryan Haight Act exemption that applied during the federal public health emergency was extended through December 2025, and proposed DEA rules suggest continued flexibility for non-scheduled drugs like alirocumab beyond that date. [10]

Alirocumab is not a controlled substance, so the stricter Ryan Haight in-person requirements that apply to controlled substances do not apply here. A board-certified cardiologist, lipidologist, endocrinologist, or primary care physician licensed in New York can prescribe Praluent via telehealth after reviewing the patient's lipid panel, medical history, and current statin regimen.

HealthRX clinicians practicing in New York follow the ACC/AHA LDL-C documentation checklist before submitting any PA for alirocumab: current LDL-C result (within 90 days), statin dose and duration, ezetimibe trial documentation, and the specific ASCVD or FH diagnosis code (ICD-10 Z82.49 for FH family history, E78.01 for heterozygous FH, or I25.10 for coronary artery disease without angina).

How Long Does Praluent Take to Work, and How Often Are Labs Needed?

LDL-C reductions with alirocumab become measurable within 2 weeks of the first injection and plateau near the 4-week mark. The ODYSSEY LONG TERM trial (N=2,341) confirmed that LDL-C reductions of approximately 61% from baseline are sustained at 78 weeks on the 150 mg dose. [11]

New York clinicians typically recheck a fasting lipid panel 4 to 6 weeks after starting alirocumab to confirm response and adjust dose if needed. If LDL-C does not fall below the target (generally 70 mg/dL for ASCVD patients or 100 mg/dL for FH without ASCVD), the dose may be increased from 75 mg to 150 mg. After the dose is stable, annual lipid panels are generally sufficient unless the clinical situation changes. Annual labs also serve as documentation supporting PA renewals for Medicaid and commercial insurance.

Injection-site reactions occur in approximately 7.2% of alirocumab patients versus 5.1% in placebo groups based on pooled Phase III data; these are typically mild and transient. [12] Neurocognitive adverse events were a concern in early trials but were not confirmed as a drug-related signal in the large ODYSSEY OUTCOMES dataset.

What Other PCSK9 Inhibitors Are Available in New York, and How Do Their Costs Compare?

Evolocumab (Repatha, Amgen) is the only other approved injectable PCSK9 inhibitor available in New York. Its WAC is approximately $575/month in 2026, nearly identical to Praluent. Inclisiran (Leqvio, Novartis) is a small interfering RNA (siRNA) drug that targets PCSK9 mRNA and is dosed twice yearly after an initial loading sequence; its WAC is approximately $3,250 per dose, or roughly $6,500/year, which is comparable on an annual basis.

The ORION-10 trial (N=1,561) showed inclisiran reduced LDL-C by 52.3% at 17 months versus placebo (P<0.001), a magnitude similar to alirocumab. [13] Inclisiran does not yet have a cardiovascular outcomes trial equivalent to ODYSSEY OUTCOMES, which influences some insurer PA decisions in New York. Prescribers choosing between agents primarily on cost should compare the savings programs for each drug, as manufacturer assistance programs can make all three options free or near-free for eligible patients.